Intra-Cellular Therapies - ITCI Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.

8 equities research analysts have issued twelve-month price objectives for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $40.00 to $75.00. On average, they anticipate the company's share price to reach $60.88 in the next year. This suggests a possible upside of 33.4% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.

Intra-Cellular Therapies' stock was trading at $52.34 at the start of the year. Since then, ITCI shares have decreased by 12.8% and is now trading at $45.62.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ITCI earnings forecast.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $0.13. The biopharmaceutical company had revenue of $55.58 million for the quarter, compared to analysts' expectations of $48.62 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 53.13% and a negative net margin of 232.11%. The company's revenue was up 177.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.85) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (10.95%), State Street Corp (2.03%), Franklin Resources Inc. (1.80%), Victory Capital Management Inc. (1.20%), Pictet Asset Management SA (1.18%) and Northern Trust Corp (0.99%). Insiders that own company stock include Andrew Satlin, Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends.

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ITCI stock can currently be purchased for approximately $45.62.

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $4.31 billion and generates $83.80 million in revenue each year. The biopharmaceutical company earns $-284,130,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis.

The company employs 512 workers across the globe.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.